Stock Scorecard
Stock Summary for Dyne Therapeutics Inc (DYN) - $18.19 as of 6/4/2026 7:18:17 PM EST
Total Score
9 out of 30
Safety Score
42 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for DYN
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for DYN
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for DYN
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for DYN
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for DYN (42 out of 100)
| Stock Price Rating (Max of 10) | 6 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for DYN
Financial Details for DYN
Company Overview |
|
|---|---|
| Ticker | DYN |
| Company Name | Dyne Therapeutics Inc |
| Country | USA |
| Description | Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The company is headquartered in Waltham, Massachusetts. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 3/31/2026 |
| Next Earnings Date | 7/27/2026 |
Stock Price History |
|
| Last Day Price | 18.19 |
| Price 4 Years Ago | 11.59 |
| Last Day Price Updated | 6/4/2026 7:18:17 PM EST |
| Last Day Volume | 1,556,901 |
| Average Daily Volume | 1,453,576 |
| 52-Week High | 25.00 |
| 52-Week Low | 8.06 |
| Last Price to 52 Week Low | 125.68% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 101.33 |
| Sector PE | 65.46 |
| 5-Year Average PE | -8.88 |
| Free Cash Flow Ratio | 3.99 |
| Industry Free Cash Flow Ratio | 31.52 |
| Sector Free Cash Flow Ratio | 33.13 |
| Current Ratio Most Recent Quarter | 19.92 |
| Total Cash Per Share | 4.56 |
| Book Value Per Share Most Recent Quarter | 5.89 |
| Price to Book Ratio | 3.56 |
| Industry Price to Book Ratio | 5.56 |
| Sector Price to Book Ratio | 7.38 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 8.90 |
| Sector Price to Sales Ratio Twelve Trailing Months | 4.69 |
| Analyst Buy Ratings | 11 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 165,314,000 |
| Market Capitalization | 3,007,061,660 |
| Institutional Ownership | 115.46% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -40.58% |
| Reported EPS 12 Trailing Months | -3.15 |
| Reported EPS Past Year | -0.73 |
| Reported EPS Prior Year | -3.51 |
| Net Income Twelve Trailing Months | -451,707,000 |
| Net Income Past Year | -446,214,000 |
| Net Income Prior Year | -317,418,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 753,102,000 |
| Total Cash Past Year | 893,369,000 |
| Total Cash Prior Year | 435,449,000 |
| Net Cash Position Most Recent Quarter | 603,727,000 |
| Net Cash Position Past Year | 744,448,000 |
| Long Term Debt Past Year | 148,921,000 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 149,375,000 |
| Equity to Debt Ratio Past Year | 0.87 |
| Equity to Debt Ratio Most Recent Quarter | 0.85 |
| Total Stockholder Equity Past Year | 972,129,000 |
| Total Stockholder Equity Prior Year | 629,838,000 |
| Total Stockholder Equity Most Recent Quarter | 865,055,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -462,186,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.80 |
| Free Cash Flow Past Year | -405,127,000 |
| Free Cash Flow Prior Year | -294,745,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.01 |
| MACD Signal | -0.09 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 1.08 |
| RSI | 50.87 |
| 50-Day SMA | 16.13 |
| 150-Day SMA | 19.51 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 6/3/2026 10:23:54 PM EST |